KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Revenue: 2009-2024

Historic Revenue for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $14.2 billion.

  • Regeneron Pharmaceuticals' Revenue rose 0.90% to $3.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 billion, marking a year-over-year increase of 2.89%. This contributed to the annual value of $14.2 billion for FY2024, which is 8.27% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Revenue of $14.2 billion as of FY2024, which was up 8.27% from $13.1 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' Revenue's 5-year high stood at $16.1 billion during FY2021, with a 5-year trough of $8.5 billion in FY2020.
  • Moreover, its 3-year median value for Revenue was $13.1 billion (2023), whereas its average is $13.2 billion.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Revenue spiked by 89.14% in 2021, and later declined by 24.26% in 2022.
  • Regeneron Pharmaceuticals' Revenue (Yearly) stood at $8.5 billion in 2020, then surged by 89.14% to $16.1 billion in 2021, then decreased by 24.26% to $12.2 billion in 2022, then rose by 7.76% to $13.1 billion in 2023, then increased by 8.27% to $14.2 billion in 2024.